Intralesional triamcinolone therapy for pretibial myxedema.
In a prospective study, nine patients with pretibial myxedema were treated with intralesional injections of triamcinolone acetonide. Complete resolution of the myxedematous plaques was obtained in seven of the nine patients. The other two patients failed to complete their treatment  programs but did show partial resolution. For most patients the monthly injection of 8 ml or less of a solution containing 5 mg/ml of triamcinolone proved to be the most effective dosage schedule. No serious side effects were encountered. New nodules of myxedema developed in some patients after the initial completion of therapy; these nodules responded to reinjection using the same dosage schedule.
D000328:Adult; D000368:Aged; D001706:Biopsy; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009230:Myxedema / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D012867:Skin / Q000473:pathology; D013977:Tibia; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000627:therapeutic use
D014222:Triamcinolone Acetonide